摘要 |
<p>Improved immunosuppression for use in antigenic biological response modifier therapies is provided by the concurrent administration of T-cell specific immunotoxins as an immunosuppressive agent. This immunosuppressive immunotoxin can comprise an anti-Pan T-cell immunoglobulin complexed with a cytotoxic agent, such as a ribosomal inhibiting protein. Compositions comprising the immunosuppressive immunotoxin with other immunosuppressive agents have been developed to permit multiple-dose regimens or extended therapies with the modifiers.</p> |